Screener
Beam Therapeutics BEAM Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Depreciation and amortization | 5,605 | 5,528 |
| Amortization of investment discount (premiums) | (2,763) | (3,849) |
| Amortization of debt discount | 35 | — |
| Stock-based compensation expense | 19,044 | 26,682 |
| Change in operating lease right-of-use assets | 2,532 | 2,649 |
| Change in fair value of derivative liabilities | (2,500) | (3,200) |
| Change in fair value of contingent consideration liabilities | (514) | 27 |
| Change in fair value of non-controlling equity investments | (16) | 2,081 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's stock-based comp?
- Beam Therapeutics (BEAM) reported stock-based comp of $19.04M in Q1 2026.
- How has Beam Therapeutics's stock-based comp changed year-over-year?
- Beam Therapeutics's stock-based comp decreased by 28.6% year-over-year, from $26.68M to $19.04M.
- What is the long-term trend for Beam Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Beam Therapeutics's stock-based comp has grown at a 21.3% compound annual growth rate (CAGR), from $43.57M to $94.24M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Beam Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude